A Second Lu-177 DOTATATE (Bexlutry) Arrives for GEP-NETs: US FDA | September 2026

What’s New?

The FDA has approved Bexlutry (lutetium Lu-177 dotatate) for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut NETs.

Bexlutry becomes a second Lu-177 dotatate option for peptide receptor radionuclide therapy (PRRT).

It is the first radioligand equivalent to Lutathera approved through the 505(b)(2) pathway.

Approval relied on established published efficacy evidence plus bridging data demonstrating comparable biological and chemical characteristics.

It does not introduce a new mechanism or expand current PRRT eligibility.

Standard PRRT considerations remain unchanged, including renal protection, radiation precautions and hematologic monitoring.

Long-term risks, including MDS and leukemia, remain relevant.

Why Does It Matter?

The significance is primarily practical: another Lu-177 dotatate product could improve PRRT availability and treatment access, particularly where radioligand supply is constrained.

GastroAGI Takeaway

This is an access advance, not an efficacy breakthrough. Bexlutry provides another FDA-approved Lu-177 dotatate option without changing the fundamental selection or treatment principles for SSTR-positive GEP-NETs.